A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma

BACKGROUND: At present, there are no definitive optimal treatment options for patients with hepatocellular carcinoma (HCC) following first-line treatment failure. To maximize the survival benefit of patients, we compared the combination therapy of regorafenib and programmed death-1 (PD-1) inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Tao, Huang, Chenyang, Peng, Caiyun, Duan, Xuezhang, Ji, Dong, Duan, Youjia, Zhang, Wen, Zhao, Haitao, Gao, Kun, Yang, Xiangyu, Zhang, Linzhi, Cheng, Jiamin, de Castria, Tiago Biachi, Pocha, Christine, Tsilimigras, Diamantis I., Wu, Tong, Su, Guodong, Li, Yinyin, Yu, Lingxiang, Lu, Yinying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929741/
https://www.ncbi.nlm.nih.gov/pubmed/36819518
http://dx.doi.org/10.21037/atm-22-6614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929741/
https://www.ncbi.nlm.nih.gov/pubmed/36819518
http://dx.doi.org/10.21037/atm-22-6614

Ejemplares similares